Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933353

SCHEMBL2933353

SCHEMBL2933353

CSc1nccc(CC(=O)c2ccccc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ GLA P06280 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NTRK1 P04629 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.41
▸ CTNNB1 P35222 1/20 0.41
▸ WNT3A P56704 1/20 0.41
▸ ALOX15 P16050 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.39
▸ CYP2C19 P33261 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HPGD P15428 3/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ PLOD2 O00469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4658932 0.88 KMT2A (0.48) RAB9ANPC1KDM4EKMT2AMAPT
SCHEMBL4420456 0.86 NPC1 (0.54) RAB9ANPC1ALDH1A1KMT2AMAPT
SCHEMBL1554048 0.86 RAB9A (0.54) RAB9ANPC1KDM4EALDH1A1KMT2A
SCHEMBL5605781 0.85 ALDH1A1 (0.41) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL5605161 0.85 ALDH1A1 (0.41) RAB9ANPC1ALDH1A1KMT2AMAPT
SCHEMBL5090955 0.84 NPC1 (0.44) RAB9ANPC1ALDH1A1KMT2AMAPT
SCHEMBL3063975 0.84 MEN1 (0.42) RAB9ANPC1ALDH1A1KMT2APOLB
SCHEMBL4423238 0.84 SYK (0.42) ALDH1A1FFAR4ALOX15
SCHEMBL13089951 0.84 RAB9A (0.40) RAB9ANPC1KDM4EALDH1A1KMT2A
SCHEMBL4428289 0.84 TDP1 (0.47) RAB9ANPC1GLAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 — — US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 — — EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 — — US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 — — US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 — — US disclosed
US-7105517-B2 Thiazolyl substituted aminopyrimidines as plant protection agents SYNGENTA CROP PROTECTION, INC. (US) 2006-09-12 — — US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 — — US disclosed
EP-1434776-B1 THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS SYNGENTA PARTICIPATIONS AG (CH) 2006-06-28 — — EP disclosed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 — — EP disclosed
EP-1224185-B1 THIAZOLE AND IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE NOVARTIS AG (CH) 2005-11-30 — — EP disclosed
WO-2003029249-A1 THIAZOLYL SUBSTITUTED AMINOPYRIMIDINES AS PLANT PROTECTION AGENTS SYNGENTA PARTICIPATIONS AG (CH) 2003-04-10 — — WO disclosed
WO-2003011837-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-13 — — WO disclosed
EP-1224180-A2 SUBSTITUTED AZOLES Novartis AG (CH) 2002-07-24 — — EP disclosed
EP-1224185-A1 THIAZOLE AND IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE Novartis AG (CH) 2002-07-24 — — EP disclosed
US-20020049220-A1 Substituted azoles NOVARTIS AG (CH) 2002-04-25 — — US disclosed
EP-1140939-A1 SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-ALPHA]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS Ortho-Mcneil Pharmaceutical, Inc. (US) 2001-10-10 — — EP disclosed
WO-2001034605-A1 SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-05-17 — — WO disclosed
WO-2001030778-A1 THIAZOLE AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE NOVARTIS AG (CH) 2001-05-03 — — WO disclosed
WO-2000063204-A2 SUBSTITUTED AZOLES NOVARTIS AG (CH) 2000-10-26 — — WO disclosed
WO-2000026209-A1 ANTI-INFLAMMATORY 4-PHENYL-5-PYRIMIDINYL-IMIDAZOLES NOVARTIS AG (CH) 2000-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 RAB9A 1459/4885NPC1 2411/4885KDM4E 3384/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 RAB9A 1378/4885NPC1 2735/4885KDM4E 3953/4885
US-20020049220-A1 Substituted azoles MAPK1, MAPK4, MAP3K1 RAB9A 1548/4885NPC1 3073/4885KDM4E 1625/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 RAB9A 1378/4885NPC1 2735/4885KDM4E 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.